arrow
F

F.M. Venanzi

vita salute san-raffaele university
H指数:8
被引数:212

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional − prospective study to inform referral for germline testing

非小细胞肺癌中的家族史信息补充:一项用于指导胚系检测转诊的横断面-前瞻性研究

2026-02-260
OAAI
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis

铂类化疗和CTLA-4抑制对非小细胞肺癌中一线抗PD-1/PD-L1药物获得性耐药的影响:一项系统综述和重构的个体患者数据分析

2025-09-020
PREAI
Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI plus CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)

评估免疫检查点抑制剂联合化疗(ICI plus CT)在早期非小细胞肺癌(NSCLC)临床试验中的不确定性和脆弱性,采用信息性删失和生存推断脆弱性指数(SIFI)进行分析。

2024-09-010
PRE
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)
2024-07-312
OAAI
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?
2023-12-013
PRE
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
2023-12-0110
PRE